ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up

The use of two medicines together (combination therapies) for previously untreated patients with RCC that has spread (metastatic RCC) is fast becoming standard treatment for these patients. A study called CheckMate-214 showed that a combination of the immune checkpoint inhibitors nivolumab plus ipilimumab helped patients with intermediate or high risk RCC live longer than those […]

read more

ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)

Ipilimumab plus nivolumab is a standard first-line treatment for patients with intermediate and poor-risk advanced RCC. Serious or life-threatening side effects are relatively common with this combination. The aim of this phase 2 trial (PRISM) was to see if changing the treatment schedule for ipilimumab in combination with nivolumab can improve tolerability of this treatment […]

read more

ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are stopped from getting to the brain by a membrane called the blood-brain barrier. Most patients with brain metastases have, therefore, been excluded from phase 3 clinical trials. In the phase 3/4 CheckMate 920 study, presented at […]

read more

ASCO 2021: Baseline characteristics affect survival with nivolumab plus cabozantinib

Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib were presented a the American Society for Clinical Oncology (ASCO) Annual Meeting over the weekend. The nivolumab/cabozantinib combination doubled the average time to when the treatment stopped working and the cancer started growing again (progression-free survival) compared to sunitinib and nearly twice […]

read more

ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer

The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This poster presentation from the American Society for Clinical Oncology (ASCO) Annual Meeting at the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab in patients […]

read more

ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This study, presented at the American Society for Clinical Oncology (ASCO) Annual Meeting held virtually over the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab […]

read more

Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment

The European Commission has approved the use of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The combination is now licensed for use within the European Union. The Medicines and Healthcare products Regulatory Agency (MHRA) will need to approve the nivolumab plus cabozantinib combination before it […]

read more

Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The European Commission will now review the CHMP recommendation and make a final decision in the next few months […]

read more

ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination

Long-term follow-up data from the CheckMate-214 study of the nivolumab plus ipilimumab combination in untreated, advanced clear cell kidney cancer patients were presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. Patients were followed for at least 4 years after treatment with nivolumab plus ipilimumab […]

read more

ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer

Data from the CheckMate-920 study on the safety and effectiveness of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) was presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. CheckMate-920 is a community-based, phase IIIb/IV clinical trial of nivolumab plus […]

read more
Showing 1 to 10 of 130 results
  TOP